Literature DB >> 8195606

Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis.

L D Heerze1, M A Kelm, J A Talbot, G D Armstrong.   

Abstract

Toxin A produced by Clostridium difficile, the causative agent of pseudomembranous colitis and antibiotic-associated diarrhea, was shown to bind to synthetic oligosaccharide sequences attached to an inert support (SYNSORB). The oligosaccharide sequences that bind to toxin A were related to sequences previously identified as potential receptors for the toxin. Various SYNSORBs containing a variety of oligosaccharides were examined for their potential to neutralize toxin A activity from toxin-containing solutions as well as clinical stool samples from patients with either pseudomembranous colitis or antibiotic-associated diarrhea. The results from neutralization experiments suggest SYNSORB can effectively neutralize toxin A activity from stool samples and thus could serve as a potential therapy for C. difficile-associated diarrhea.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195606     DOI: 10.1093/infdis/169.6.1291

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Evaluation of a new enzyme immunoassay for Clostridium difficile toxin A.

Authors:  S O Vargas; D Horensky; A B Onderdonk
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

2.  Treatment of Recurrent Clostridium difficile Diarrhea.

Authors:  Elizabeth S Huebner; Christina M Surawicz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-03

3.  Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells.

Authors:  Kari Shoaf; George L Mulvey; Glen D Armstrong; Robert W Hutkins
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

4.  GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis.

Authors:  C B Kurtz; E P Cannon; A Brezzani; M Pitruzzello; C Dinardo; E Rinard; D W Acheson; R Fitzpatrick; P Kelly; K Shackett; A T Papoulis; P J Goddard; R H Barker; G P Palace; J D Klinger
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 5.  The host immune response to Clostridium difficile infection.

Authors:  Katie Solomon
Journal:  Ther Adv Infect Dis       Date:  2013-02

Review 6.  Non-systemic drugs: a critical review.

Authors:  Dominique Charmot
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.